FTO (Freedom to operate) in the pharmaceutical industry /
Saved in:
| Author / Creator: | Nonaka, Hirotaka, author. |
|---|---|
| Edition: | 1st edition. |
| Imprint: | Baden-Baden : Nomos, 2018. |
| Description: | 1 online resource |
| Language: | English |
| Series: | MIPLC studies ; volume 34 MIPLC studies ; v. 34. |
| Subject: | |
| Format: | E-Resource Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/11738032 |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | 11738032 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 181221s2018 gw ob 000 0 eng d | ||
| 005 | 20220624111547.0 | ||
| 020 | |a 9783845294018 |q (electronic bk.) | ||
| 020 | |a 3845294019 |q (electronic bk.) | ||
| 020 | |z 3848752212 | ||
| 020 | |z 9783848752218 | ||
| 035 | |a (OCoLC)1079910283 | ||
| 035 | 9 | |a (OCLCCM-CC)1079910283 | |
| 037 | |a 22573/ctv933mxt |b JSTOR | ||
| 040 | |a JSTOR |b eng |e rda |e pn |c JSTOR |d ICN |d SOI |d OCLCF |d ERL |d C6I |d VT2 |d UKKNU |d OCLCQ |d OCLCO |d YDX | ||
| 049 | |a MAIN | ||
| 050 | 4 | |a HD9665.5 | |
| 100 | 1 | |a Nonaka, Hirotaka, |e author. | |
| 245 | 1 | 0 | |a FTO (Freedom to operate) in the pharmaceutical industry / |c Hirotaka Nonaka. |
| 250 | |a 1st edition. | ||
| 264 | 1 | |a Baden-Baden : |b Nomos, |c 2018. | |
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a data file | ||
| 490 | 1 | |a MIPLC studies ; |v volume 34 | |
| 504 | |a Includes bibliographical references. | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Key features of innovation in the pharmaceutical industry -- How to achieve freedom to operate (FTO) -- Dealing with adverse patents -- Structure and operation of FTO-licensing markets in the parmaceutical industry -- FTO-licensing between a venture business company for innovative drug development and a pharmaceutical company. | |
| 520 | |a Die FTO-Lizensierung in der Pharmaindustrie verdient aufgrund der wirtschaftlichen Bedeutsamkeit des Marktes, der hohen Kosten von Forschung und Entwicklung, einer extrem niedrigen Erfolgsrate sowie der einfachen Duplizierbarkeit des Medikaments besonderes Augenmerk. Unter Berücksichtigung dieser speziellen Aspekte erklärt der Autor zunächst, wie man eine FTO-Recherche korrekt ausführt und einen entsprechenden FTO-Lizenzvertrag abschließt. Anschließend zeigt er zwei Probleme auf: die Frage des Wettbewerbs innerhalb der EU, vor allem die unangemessene Umsetzung der Richtlinie, sowie die Unterscheidung zwischen Bio-Venture- und Pharmaunternehmen. Für diese Probleme schlägt der Autor Lösungen vor.Hirotaka Nonaka ist Rechts- und Patentanwalt in Tokio (Japan) und vor allem im Bereich Rechtsstreitigkeiten im Zusammenhang mit geistigem Eigentum sowie in der Beratung tätig. | ||
| 650 | 0 | |a Pharmaceutical industry. |0 http://id.loc.gov/authorities/subjects/sh85039713 | |
| 650 | 0 | |a Drug development. |0 http://id.loc.gov/authorities/subjects/sh97007921 | |
| 650 | 0 | |a Patent infringement. |0 http://id.loc.gov/authorities/subjects/sh96001068 | |
| 650 | 0 | |a Patent searching. |0 http://id.loc.gov/authorities/subjects/sh85098653 | |
| 650 | 2 | |a Drug Industry |0 https://id.nlm.nih.gov/mesh/D004345 | |
| 650 | 6 | |a Industrie pharmaceutique. | |
| 650 | 6 | |a Médicaments |x Développement. | |
| 650 | 6 | |a Brevets d'invention |x Contrefaçon. | |
| 650 | 6 | |a Brevets d'invention |x Recherche documentaire. | |
| 650 | 7 | |a Law |x International. |2 bisacsh | |
| 650 | 7 | |a Drug development. |2 fast |0 (OCoLC)fst00898670 | |
| 650 | 7 | |a Patent infringement. |2 fast |0 (OCoLC)fst01054821 | |
| 650 | 7 | |a Patent searching. |2 fast |0 (OCoLC)fst01054858 | |
| 650 | 7 | |a Pharmaceutical industry. |2 fast |0 (OCoLC)fst01060129 | |
| 655 | 4 | |a Electronic books. | |
| 776 | 0 | 8 | |i Print version: |a NONAKA, HIROTAKA. |t FTO FREEDOM TO OPERATE IN THE PHARMACEUTICAL INDUSTRY. |d [Place of publication not identified] : NOMOS VERLAGSGESELLSCHAFT, 2018 |z 3848752212 |w (OCoLC)1053866145 |
| 830 | 0 | |a MIPLC studies ; |v v. 34. |0 http://id.loc.gov/authorities/names/no2009009423 | |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/48170 |y Open Access Publishing in European Networks |
| 856 | 4 | 0 | |u https://www.jstor.org/stable/10.2307/j.ctv941tn6 |y JSTOR |
| 901 | |a OpenAccess | ||
| 903 | |a HeVa | ||
| 929 | |a oclccm | ||
| 999 | f | f | |i 6570bb5d-fcbb-5f04-a99a-a5594db9ad90 |s 97e30fc8-a610-53ce-be76-8778b1ccd3f8 |
| 928 | |t Library of Congress classification |a HD9665.5 |l Online |c UC-FullText |u https://directory.doabooks.org/handle/20.500.12854/48170 |z Open Access Publishing in European Networks |u https://www.jstor.org/stable/10.2307/j.ctv941tn6 |z JSTOR |g ebooks |i 12715445 | ||